Lead Product(s): D-Tryptophanol
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 07, 2020
The funding will help the company to initiate Phase 2b clinical trial for the treatment of medically refractory epilepsy in 2020.